Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases

Breast Journal

Volumn 16, Issue 1, 2010, Pages 32-37

  Wang, Xin ^a   Zhao, Ying ^b   Xuchen, Cao ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Axillary mestastasis; Chemotherapy; Occult breast carcinoma; Radiotherapy; Surgery

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M4G3; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; ECHOMAMMOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; METASTASIS; PALPATION;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AXILLA; BREAST NEOPLASMS; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC DISEASES; LYMPHATIC METASTASIS; MAMMOGRAPHY; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ULTRASONOGRAPHY, MAMMARY;

EID: 77249117763     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2009.00848.x     Document Type: Article

References (27)

1. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;46:1-19.
2. Cameron HC. Some clinical facts regarding mammary cancer. BMJ 1909;1:577-82.
3. Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol 1990;21:518-23.
4. Kemeny MM, Rivera DE, Terz JJ, et al. Occult primary adenocarcinoma with axillary metastases. Am J Surg 1986;152:43-7.
5. Merson M, Andreola S, Galimberti V, et al. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 1992;70:504-8.
6. Baron PL, Moore MP, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg 1990;125:210-4.
7. Vilcoq JR, Calle R, Ferme F, et al. Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch Surg 1982;117:1136-8.
8. Blanchard DK, Farley DR. Retrospective study of women presenting with axillary metastases from occult breast carcinoma. World J Surg 2004;28:535-9.
9. Brenin DR. The unknown primary tumor presenting with axillary lymphadenopathy. In: Singletary SE, Robb GL, Hortobagyi GN, eds. Advanced Therapy of Breast Disease. London: BC Decker, 2004:659-65.
10. Niu Y, Fu X, Niu R. Significance of the monoclonal antibody M4G3 against human breast cancer in the diagnosis of the occult breast cancer. Chin J Exp Surg 2003;20:654-6.
11. Niu Y, Fan Y, Fu X. [Whole organ subserial section examination of occult breast carcinoma]. Zhonghua Zhong Liu Za Zhi 1995;17:298-300.
12. Huang J, Liu X, Zhou Y, et al. The monoclonal antibodies against human breast cancer specific glycoproteins: it's production and the study on immunopathology. Acta Oncol Sinica 1993;3:280-3.
13. Dockerty MB, Gray HK, Pierce EH. Surgical significance of isolated axillary adenopathy. Ann Surg 1957;145:104-7.
14. Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology 1996;29:233-40.
15. Obdeijn IM, Brouwers-Kuyper EM, Tilanus-Linthorst MM, et al. MR imaging-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast. AJR Am J Roent-genol 2000;174:1079-84.
16. Olson JA Jr, Morris EA, Van Zee KJ, et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000;7:411-5.
17. Orel SG, Weinstein SP, Schnall MD, et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 1999;212:543-9.
18. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2- deoxy-D-glucose. J Natl Cancer Inst 1996;88:1204-9.
19. Yamaguchi H, Ishikawa M, Hatanaka K, et al. Occult breast cancer presenting as axillary metastases. Breast 2006;15:259-62.
20. Kelly TA, Kim JA, Patrick R, et al. Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg 2003;186:368-70.
21. Sakr R, Barranger E, Antoine M, et al. Ductal carcinoma in situ: value of sentinel lymph node biopsy. J Surg Oncol 2006; 94:426-30.
22. Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys 2000;47:143-7.
23. Jackson B, Scott-Conner C, Moulder J. Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg 1995;61:431-4.
24. van Ooijen B, Bontenbal M, Henzen-Logmans SC, et al. Axillary nodal metastases from an occult primary consistent with breast carcinoma. Br J Surg 1993;80:1299-300.
25. Vlastos G, Jean ME, Mirza AN, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 2001;8:425-31.
26. Medina-Franco H, Urist MM. Occult breast carcinoma presenting with axillary lymph node metastases. Rev Invest Clin 2002;54:204-8.
27. Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. Am J Surg 2005;190:609-13.